Pfenex (PFNX) Reports Third Quarter 2016 Results And Provides Business Update
11/10/2016 4:49:25 PM
SAN DIEGO, Nov. 9, 2016 /PRNewswire/ -- Pfenex Inc. (NYSE MKT: PFNX), a clinical-stage biotechnology company engaged in the development of biosimilar therapeutics, including high value and difficult to manufacture proteins, today reported financial results for the third quarter ended September 30, 2016 and provided a business update.
"In the third quarter, Pfenex has continued to make steady progress, advancing our broad pipeline of biosimilar therapeutics and government funded anthrax vaccine candidates," stated Bertrand C. Liang, Chief Executive Officer of Pfenex. "This quarter we announced several important updates, including the formation of our Scientific Advisory Board and the hiring of Steven Sandoval as our Chief Manufacturing Officer. The addition of these key resources will support the advancement of our portfolio towards commercialization. We are looking forward to sharing additional product updates and data over future quarters."
comments powered by